Tag:
Xgeva
Latest Headlines
Latest Headlines
Amgen gets a no from the FDA on extended use of Xgeva
The FDA told Amgen no to an expanded use of its cancer treatment Xgeva, one of the company's most important drugs, saying the company could try again with more data.
FDA panel nixes new use for Amgen's Xgeva
The FDA's expert advisors didn't buy Amgen's ( $AMGN ) argument for earlier use of its bone drug Xgeva in prostate cancer patients. The idea: Treat advanced prostate cancer patients with...
Amgen's Xgeva faces FDA skepticism
The FDA isn't convinced that Amgen ( $AMGN ) needs another bone-metastasis indication for its new drug Xgeva . The drug is already approved to treat skeletal side effects in cancer patients, but Amgen
Amgen's Xgeva faces doubters on new indication
The FDA isn't convinced that Amgen ( $AMGN ) needs another bone-metastasis indication for its new drug Xgeva . The drug is already approved to treat skeletal side effects in cancer patients, but Amgen
Amgen's new meds beat estimates as anemia drugs slip
Amgen's ( $AMGN ) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen . New bone drugs Xgeva and Prolia beat analyst estimates for their first full
Amgen aims for growth in bone drugs, overseas markets
Amgen's ( $AMGN ) incoming CEO has high hopes for this year. Now COO, Robert Bradway says he's looking for revenue growth in 2012, thanks in part to international expansion. Another driver: Sales of
Amgen's Prolia wins new uses, performs in study
It's a good news-good news day for Amgen ( $AMGN ). The company's new bone drug is gathering indications--and potential sales--like a snowball rolling downhill. Under the name Prolia, the drug won FDA
Breakthrough meds deliver the goods for BMS, Vertex
Fear not, pharma. There really might be hope ahead. Or such is the feeling among analysts chuffed by the early success of three new drugs. You know the ones: Bristol-Myers Squibb's melanoma drug
AZ to co-promote Amgen bone drug in Japan
AstraZeneca has signed on to promote Amgen's bone drug denosumab in Japan. The deal with Daiichi Sankyo, which holds the Japanese rights to the drug, gives AZ a promising new treatment to sell in a
CHMP recommends approval of a host of new drugs
Some big news has come out of a key advisory committee for European drug approvals. In addition to backing approval of Merck's ( $MRK ) hepatitis C drug Victrelis ( boceprevir ), European Medicines
